CD276 and pancreatic ductal adenocarcinoma: B7-H3 CAR-T cells have shown more safety and less toxicity when treating malignant tumors in the nervous system and pancreatic ductal adenocarcinoma [17,29]; however, the safety of B7-H3 CAR-T cells has been proven in other models only at the 2 week window post T cell infusion [17].